Years ended December 31,

2015

2014

2013

Supplemental disclosures of Cash Flow Information:

Cash (received) paid for income taxes, net

$

(352)

$

4,217

$

1,265

Cash paid for interest

30,207

6,451

2,733

Supplemental disclosures of Non-cash Investing and Financing Activities:

Conversion of 8.00% Convertible notes

60,172

-

Issuance of 1,682,086 shares to Zogenix for Zohydro acquisition

11,926

-

Acquisition of TREXIMET® - warrants issued to Pozen

-

2,359

-

Accrued severance paid in restricted common stock

-

142

Acquisition of Cypress and Somaxon - Purchase price adjustment

-

(990)

5,412

Acquisition of Somaxon - Fair value of common stock

-

24,840

Warrants issued to Frontline in connection with the issuance of the

8% Convertible Notes

-

841

-

Acquisition of license - contract payable

-

500